🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Multiple Myeloma, Smoldering

Promoting Diagnosis and Management of AL in Italy (ProDigALIty) NCT06383143n/a4 sites📍 Bari📍 Catania📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia · Tests: no intervention Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial NCT06212323n/a1 site📍 Salt Lake City University of Utah · Tests: Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI. FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease NCT07446777NA1 site📍 Miami University of Miami · Tests: Health Coaching, Prolonged Overnight Fasting (POF), Mediterranean Diet, Supportive Materials Screening for AL Amyloidosis in Smoldering Multiple Myeloma NCT06365060n/a13 sites📍 Birmingham📍 Los Angeles📍 San Francisco Tufts Medical Center A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma NCT06140524Phase 239 sites📍 Baltimore📍 Boston📍 Ann Arbor Regeneron Pharmaceuticals · Tests: Linvoseltamab A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH NCT05283993n/a1 site📍 Beijing Peking University First Hospital · Tests: No intervention The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma NCT05841550Phase 1, Phase 21 site📍 Oslo Oslo University Hospital · Tests: TG01 A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma NCT05055063Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Belantamab mafodotin Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma NCT05312255NA1 site📍 Buffalo Roswell Park Cancer Institute · Tests: Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol, Quality-of-Life Assessment, Questionnaire Administrat… Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma NCT03937635Phase 3748 sites📍 Birmingham📍 Anchorage📍 Anchorage ECOG-ACRIN Cancer Research Group · Tests: Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration Whole Body MRI in Oncology NCT06895291n/a3 sites📍 Bologna📍 Meldola📍 Milan Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: Whole Body-Magnetic Resonance Imaging (WB-MRI) Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma NCT04776395Phase 21 site📍 Atlanta Emory University · Tests: Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study NCT06644625n/a1 site📍 Charlotte Wake Forest University Health Sciences · Tests: Blood draw for the laboratory assessment A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) NCT07393282Phase 327 sites📍 Phoenix📍 Atlanta📍 Boston Regeneron Pharmaceuticals · Tests: Linvoseltamab, Daratumumab Immuno-PRISM (PRecision Intervention Smoldering Myeloma) NCT05469893Phase 23 sites📍 Denver📍 Boston📍 Portland Irene Ghobrial, MD · Tests: Teclistamab, Lenalidomide, Dexamethasone A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma NCT07069751NA5 sites📍 Milan📍 Bari📍 Milan Ciceri Fabio · Tests: diet rich in fiber Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions NCT05361694n/a1 site📍 Miami University of Miami A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS) NCT06055894NA7 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Omega-3, Curcumin, Probiotic, Whole food, plant-based diet (WFPBD) A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma NCT06768489Phase 116 sites📍 Denver📍 Atlanta📍 Clayton Janssen Research & Development, LLC · Tests: JNJ-79635322, Daratumumab, Pomalidomide, Lenalidomide BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma NCT06745687NA1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CM336 Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma NCT05597345Phase 21 site📍 Rochester University of Rochester · Tests: Selinexor Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma NCT02726750n/a1 site📍 Houston M.D. Anderson Cancer Center · Tests: Biospecimen Collection, Laboratory Biomarker Analysis Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies NCT05136807n/a1 site📍 Houston M.D. Anderson Cancer Center · Tests: Quality-of-Life Assessment, Questionnaire Administration Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution NCT07214324n/a4 sites📍 Bologna📍 Catania📍 Palermo Azienda USL Reggio Emilia - IRCCS · Tests: Collection of biological material Registry for Adults With Plasma Cell Disorders (PCD's) NCT03717844n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma NCT06762769Phase 214 sites📍 Leeds📍 Oxford📍 Aberdeen University College, London · Tests: Isatuximab, Iberdomide, Dexamethasone The Indiana Myeloma Registry NCT03616483n/a1 site📍 Indianapolis Indiana University · Tests: This is a non-interventional trial Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma NCT06574126Phase 21 site📍 Salamanca PETHEMA Foundation · Tests: Group 1: Dara-VRD followed by apheresis and cilta-cel infusion, Group 2: Apheresis followed by Dara-VRD and cilta-cel i… Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) NCT06100237Phase 21 site📍 Miami Carl Ola Landgren, MD, PhD · Tests: Teclistamab, Talquetamab, Daratumumab SC Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome NCT02269592n/a7 sites📍 Boston📍 Brighton📍 Methuen Dana-Farber Cancer Institute
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy